Stent material for promoting vascularized bone tissue regeneration and preparation method thereof

By introducing gentiopicroside into the biological scaffold material, the problem of insufficient vascularization of the biological scaffold material in bone defect repair was solved, achieving efficient, safe and economical bone tissue regeneration, and overcoming the shortcomings of traditional growth factor therapy.

CN121059892APending Publication Date: 2025-12-05SHENZHEN INST OF ADVANCED TECH +1
0 Cites 0 Cited by

Patent Information

Application Number
CN202511077027.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-08-01
Publication Date
2025-12-05

AI Technical Summary

Technical Problem

Existing biological scaffold materials lack effective vascularization function in bone defect repair, resulting in insufficient osteogenic activity, which prolongs the tissue regeneration and repair time. Furthermore, traditional growth factor therapies are costly, have poor stability, and pose risks of side effects.

Method used

By modifying bio-scaffold materials with gentianin, a small molecule active ingredient from traditional Chinese medicine, and preparing porous scaffolds using 3D printing and freeze-drying technology, we can significantly promote angiogenesis during bone repair and avoid dependence on expensive and unstable growth factors.

Benefits of technology

It significantly improves bone repair efficiency, shortens tissue regeneration cycle, reduces treatment costs, avoids side effect risks, and provides a safe, efficient, and economical vascularized bone regeneration solution.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides a scaffold material for promoting vascularized bone tissue regeneration and a preparation method thereof, the scaffold material for promoting vascularized bone tissue regeneration is a biological scaffold material based on traditional Chinese medicine active micromolecule gentiopicroside modification, and aims to solve the problem that the biological scaffold material in bone repair is insufficient in vascular regeneration capacity. The core of the strategy is that the GPD is utilized to modify the biological scaffold, and the revascularization in the bone repair process is remarkably promoted, so that the dependence on poor-stability and expensive vascular growth factors (such as VEGF (vascular endothelial growth factor), PDGF-BB (PDGF-BB) and the like) is avoided. Therefore, the gentiopicroside shows a huge application prospect in the field of bone repair, especially in the aspect of large-area bone defect vascular regeneration.
Need to check novelty before this filing date? Find Prior Art